SCHEMBL16833549

SCHEMBL16833549

CC(C)c1cc(C(=O)O)c2cc(Br)ccc2n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 3/20 0.64
▸ RXFP1 Q9HBX9 6/20 0.56
▸ MEN1 O00255 5/20 0.56
▸ KMT2A Q03164 5/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ ALDH1A1 P00352 5/20 0.53
▸ KDM4E B2RXH2 5/20 0.53
▸ PPARG P37231 4/20 0.53
▸ NCOR2 Q9Y618 4/20 0.53
▸ L3MBTL1 Q9Y468 3/20 0.53
▸ POLB P06746 3/20 0.53
▸ MAPT P10636 2/20 0.53
▸ HPGD P15428 2/20 0.53
▸ RECQL P46063 2/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ GLA P06280 1/20 0.53
▸ NR4A1 P22736 1/20 0.53
▸ MCL1 Q07820 1/20 0.53
▸ ESR1 P03372 1/20 0.51
▸ PLA2G1B P04054 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11669167 0.80 ALDH1A1 (0.71) DHODHRXFP1MEN1KMT2ANPC1
SCHEMBL3948079 0.80 DHODH (0.61) DHODHRXFP1MEN1KMT2ANPC1
SCHEMBL13919569 0.78 RXFP1 (0.57) DHODHRXFP1MEN1KMT2ANPC1
SCHEMBL5015458 0.78 RXFP1 (0.57) DHODHRXFP1MEN1KMT2ANPC1
SCHEMBL30120604 0.78 RXFP1 (0.57) DHODHRXFP1MEN1KMT2ANPC1
SCHEMBL31266680 0.76 DHODH (0.62) DHODHRXFP1MEN1KMT2ANPC1
SCHEMBL25735933 0.76 RXFP1 (0.56) DHODHRXFP1MEN1KMT2ANPC1
SCHEMBL16832575 0.74 RXFP1 (0.56) DHODHRXFP1MEN1KMT2ANPC1
SCHEMBL117430 0.74 EPRS1 (0.79) DHODHRXFP1MEN1KMT2ANPC1
SCHEMBL8351404 0.74 KDM4E (0.68) DHODHRXFP1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-02-09 — — US disclosed
EP-3083598-A1 GLUCOSE TRANSPORT INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2016-10-26 — — EP disclosed
CN-106029647-A Glucose transport inhibitors 拜耳制药股份公司 2016-10-12 — — CN disclosed
WO-2015091428-A1 GLUCOSE TRANSPORT INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037028-A1 GLUCOSE TRANSPORT INHIBITORS SLC2A1, SLC2A2, SLC2A4 DHODH 699/4885RXFP1 2852/4885MEN1 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback